Nemaura Medical Inc. (NMRD)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -7.28 Million USD | -11.31% |
| 2022 | -7.34 Million USD | -63.54% |
| 2021 | -4.48 Million USD | 4.97% |
| 2020 | -4.72 Million USD | -6.31% |
| 2019 | -4.44 Million USD | -136.38% |
| 2018 | -1.87 Million USD | -22.79% |
| 2017 | -1.53 Million USD | -0.56% |
| 2016 | -1.52 Million USD | -16.0% |
| 2015 | -1.31 Million USD | -125.81% |
| 2014 | -581.13 Thousand USD | 29.8% |
| 2013 | -827.84 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.96 Million USD | 41.42% |
| 2024 Q3 | -1.46 Million USD | 92.42% |
| 2024 Q2 | -1.91 Million USD | -11.8% |
| 2023 Q2 | -1.55 Million USD | 26.59% |
| 2023 FY | - USD | -11.31% |
| 2023 Q4 | -2.24 Million USD | -318.15% |
| 2023 Q3 | -537.41 Thousand USD | 65.34% |
| 2023 Q1 | -2.11 Million USD | 10.22% |
| 2022 Q4 | -2.35 Million USD | -35.64% |
| 2022 Q1 | -1.58 Million USD | -17.4% |
| 2022 Q2 | -1.66 Million USD | -5.35% |
| 2022 Q3 | -1.73 Million USD | -3.9% |
| 2022 FY | - USD | -63.54% |
| 2021 Q3 | -1.04 Million USD | 13.78% |
| 2021 FY | - USD | 4.97% |
| 2021 Q4 | -1.34 Million USD | -29.66% |
| 2021 Q1 | -890.86 Thousand USD | 33.5% |
| 2021 Q2 | -1.2 Million USD | -35.51% |
| 2020 Q2 | -1.09 Million USD | 11.61% |
| 2020 Q1 | -1.24 Million USD | 22.87% |
| 2020 FY | - USD | -6.31% |
| 2020 Q4 | -1.33 Million USD | -28.79% |
| 2020 Q3 | -1.04 Million USD | 5.42% |
| 2019 Q1 | -765.18 Thousand USD | -36.4% |
| 2019 FY | - USD | -136.38% |
| 2019 Q4 | -1.61 Million USD | -75.2% |
| 2019 Q3 | -920.65 Thousand USD | 19.56% |
| 2019 Q2 | -1.14 Million USD | -49.57% |
| 2018 Q4 | -560.98 Thousand USD | -19.63% |
| 2018 Q3 | -468.91 Thousand USD | -7.17% |
| 2018 Q2 | -437.55 Thousand USD | -6.14% |
| 2018 Q1 | -412.25 Thousand USD | -16.31% |
| 2018 FY | - USD | -22.79% |
| 2017 FY | - USD | -0.56% |
| 2017 Q4 | -354.43 Thousand USD | 4.41% |
| 2017 Q3 | -370.77 Thousand USD | -17.2% |
| 2017 Q2 | -316.36 Thousand USD | 35.34% |
| 2017 Q1 | -489.26 Thousand USD | -18.53% |
| 2016 Q1 | -398.74 Thousand USD | 25.32% |
| 2016 FY | - USD | -16.0% |
| 2016 Q4 | -412.76 Thousand USD | -26.93% |
| 2016 Q3 | -325.18 Thousand USD | 15.65% |
| 2016 Q2 | -385.53 Thousand USD | 3.31% |
| 2015 Q4 | -533.91 Thousand USD | -244.34% |
| 2015 FY | - USD | -125.81% |
| 2015 Q1 | -267.84 Thousand USD | -68.18% |
| 2015 Q2 | -355.46 Thousand USD | -32.71% |
| 2015 Q3 | -155.05 Thousand USD | 56.38% |
| 2014 Q1 | -61.05 Thousand USD | 70.5% |
| 2014 Q3 | -339.05 Thousand USD | -1457.87% |
| 2014 Q4 | -159.25 Thousand USD | 53.03% |
| 2014 FY | - USD | 29.8% |
| 2014 Q2 | -21.76 Thousand USD | 64.35% |
| 2013 Q4 | -206.96 Thousand USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | 45.97% |
| Biotricity, Inc. | -8.82 Million USD | 17.458% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -646.619% |
| PetVivo Holdings, Inc. | -10.49 Million USD | 30.563% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -249.173% |
| Sonendo, Inc. | -54.76 Million USD | 86.695% |
| Telesis Bio, Inc. | -40.49 Million USD | 82.004% |
| Talis Biomedical Corporation | -66.04 Million USD | 88.967% |
| Viveve Medical, Inc. | -20.61 Million USD | 64.655% |